Progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma

被引:2
|
作者
Liu, Tong [1 ]
Meng, Guorui [1 ]
Ma, Shihui [1 ]
You, Junqi [1 ]
Yu, Liang [1 ]
He, Risheng [1 ]
Zhao, Xudong [1 ]
Cui, Yunfu [1 ]
机构
[1] Harbin Med Univ, Affiliated Hosp 2, Dept Hepatopancreatobiliary Surg, Harbin, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2024年 / 15卷
关键词
hepatocellular carcinoma; immune checkpoint inhibitors; immunotherapy; tumor immune microenvironment; review; OPEN-LABEL; INFUSION CHEMOTHERAPY; PLUS; MULTICENTER; BEVACIZUMAB; SINTILIMAB; LENVATINIB; EFFICACY; THERAPY; SAFETY;
D O I
10.3389/fimmu.2024.1455716
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Among primary liver cancers, hepatocellular carcinoma is the most common pathological type. Its onset is insidious, and most patients have no obvious discomfort in the early stage, so it is found late, and the opportunity for surgical radical treatment is lost, resulting in a poor prognosis. With the introduction of molecular-targeted drugs represented by sorafenib, patients with middle- and late-stage liver cancer have regained the light of day. However, their therapeutic efficacy is relatively low due to the limited target of drug action, toxic side effects, and other reasons. At this time, the emergence of immunotherapy represented by immune checkpoint inhibitors (ICIs) well breaks this embarrassing situation, which mainly achieves the anti-tumor purpose by improving the tumor immune microenvironment. Currently, ICI monotherapy, as well as combination therapy, has been widely used in the clinic, further prolonging the survival of patients with advanced hepatocellular carcinoma. This article reviews the development of monotherapy and combination therapy for ICIs in advanced hepatocellular carcinoma and the latest research progress.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma
    Yin, Xiaoqiang
    Wu, Tongchui
    Lan, Yadong
    Yang, Wulin
    BIOSCIENCE REPORTS, 2022, 42 (02)
  • [2] Lenvatinib With or Without Immune Checkpoint Inhibitors in Subsets of Advanced Hepatocellular Carcinoma
    Teng, Yu-xian
    Guo, Ping-Ping
    Qin, Ke-Zhang
    Chen, Kang
    Papatheodoridis, George
    Xiang, Bang-De
    Mia, Liang
    Zhong, Jian-Hong
    EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY, 2022, 6 (01): : 25 - 29
  • [3] Current progress and prospect of immune checkpoint inhibitors in hepatocellular carcinoma
    Zeng, Zhu
    Yang, Biao
    Liao, Zheng-Yin
    ONCOLOGY LETTERS, 2020, 20 (04)
  • [4] Cancer Immunotherapy - Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
    Bai, Jing
    Liang, Ping
    Li, Qian
    Feng, Rui
    Liu, Jiang
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2021, 16 (02) : 239 - 248
  • [5] Adverse events of immune checkpoint inhibitors in hepatocellular carcinoma: a systemic review and meta-analysis
    Tian, Jin-Cheng
    Liu, Hui
    Yan, Lun-Jie
    Ding, Zi-Niu
    Han, Cheng-Long
    Tian, Bao-Wen
    Tan, Si-Yu
    Dong, Zhao-Ru
    Wang, Dong-Xu
    Xue, Jun-Shuai
    Mao, Xin-Cheng
    Yan, Yu-Chuan
    Li, Tao
    CLINICAL AND EXPERIMENTAL MEDICINE, 2023, 23 (06) : 2115 - 2129
  • [6] Radiation and Immune Checkpoint Inhibitors: Combination Therapy for Treatment of Hepatocellular Carcinoma
    Chami, Perla
    Diab, Youssef
    Khalil, Danny N.
    Azhari, Hassan
    Jarnagin, William R.
    Abou-Alfa, Ghassan K.
    Harding, James J.
    Hajj, Joseph
    Ma, Jennifer
    El Homsi, Maria
    Reyngold, Marsha
    Crane, Christopher
    Hajj, Carla
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (23)
  • [7] Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma
    Chen, Yue
    Hu, Haoyue
    Yuan, Xianglei
    Fan, Xue
    Zhang, Chengda
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [8] Immune-Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Synopsis of Response Rates
    Shek, Dmitrii
    Read, Scott A.
    Nagrial, Adnan
    Carlino, Matteo S.
    Gao, Bo
    George, Jacob
    Ahlenstiel, Golo
    ONCOLOGIST, 2021, 26 (07) : E1216 - E1225
  • [9] Surrogate end points for survival in patients with advanced hepatocellular carcinoma treated with immune checkpoint inhibitors
    Zhu, Andrew X.
    Lin, Yong
    Ferry, David
    Widau, Ryan C.
    Saha, Abhijoy
    IMMUNOTHERAPY, 2022, 14 (16) : 1341 - 1351
  • [10] Dual immune checkpoint inhibitors or combined with anti-VEGF agents in advanced, unresectable hepatocellular carcinoma
    Zhang, Bo
    Tao, Baorui
    Li, Yitong
    Yi, Chenhe
    Lin, Zhifei
    Ma, Yue
    Han, Jiahao
    Shao, Weiqing
    Chen, Zhenmei
    Lin, Jing
    Chen, Jinhong
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2023, 111 : 37 - 46